PET imaging of dynorphin/kappa-opioid reactivity to stress in depression
PET imaging of dynorphin/kappa-opioid reactivity to stress in depression
批准号:
10705218
负责人:
Elizabeth Adams Bartlett
金额:
$18.13万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-15 至 2027-08-31
关键词:
AccelerationAddictive BehaviorAdrenal GlandsAgonistAnhedoniaAnteriorAnxietyAutopsyAwardBiologicalBiologyBiomedical EngineeringBrainBrain imagingBrain regionBrain scanCellular PhoneCharacteristicsClinicDSM-VDepressed moodDevelopmentDiagnosisDisease remissionDrug TargetingDynorphinsEcological momentary assessmentExhibitsFunctional disorderGoalsHumanHydrocortisoneHypothalamic structureImageIndividualInterventionLaboratoriesLifeLife StressLinkMRI ScansMagnetic Resonance ImagingMajor Depressive DisorderMeasurableMeasuresMediatingMental DepressionMental disordersMood DisordersNeurobiologyOpioid Receptor BindingOutcome StudyParticipantPathogenesisPeripheralPhysiologicalPilot ProjectsPituitary GlandPositron-Emission TomographyPrincipal InvestigatorProcessRegulationReportingResearchRestRodentRoleSensitivity and SpecificitySeveritiesStandardizationStressStructureTestingThickTracerTrainingWorkbiological adaptation to stressdepressive symptomsdesigndisabilitydrug developmentdysphoriaefficacious treatmentfollow-uphypothalamic-pituitary-adrenal axisimprovedin vivoin vivo monitoringinnovationinvestigator trainingkappa opioid receptorsmultimodal neuroimagingneuralneural correlateneurobiological mechanismpersonalized medicinepre-clinicalprogramsprospectivepsychologicresearch studyresponsesingle episode major depressive disorderskillssocialstress reactivitystressorsymptomatologytherapeutic targettraittransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT: Major depressive disorder (MDD) is a leading cause of disability worldwide
with a paucity of personalized, efficacious treatments. Life stressors have long been shown to potently predict
depressive symptomatology and onset of major depressive episodes. Despite this, the neurobiological
mechanisms underlying stress regulation in depression are not yet fully understood in humans. Preclinical and
initial human studies implicate kappa-opioid receptor (KOR) deficits in the pathogenesis of MDD and suggest
that stress reactivity might contribute to these KOR deficits. The innovative study proposed in this K01 represents
a first step to determine if KOR binding deficits and heightened dynorphin/KOR-mediated stress reactivity are
observed in MDD relative to healthy controls (HCs). If shown to be so, then the second step will be to determine
whether these deficits represent a state effect that it is present in currently depressed and not in euthymic
subjects with MDD or a trait effect present in both currently depressed and remitted MDD (to be tested in a
follow-up R01). Therefore, we seek to evaluate KOR binding at rest and endogenous dynorphin release to a
laboratory stressor in unmedicated, currently depressed participants with MDD vs. HCs. KOR binding and
dynorphin release will be quantified in vivo in humans with functional positron emission tomography (PET) with
the new tracer [11C]EKAP, already reliably synthesized and used in rodents at the Columbia PET Center, that
targets KOR with high sensitivity and specificity. A brief, validated stress task with physiologic and psychologic
components will be given during the PET scan that elicits hypothalamic-pituitary-adrenal (HPA) axis activation.
Physiologic markers of HPA activation will be acquired proximal to the task, e.g., cortisol, to be compared with
KOR binding at rest and stress-induced endogenous dynorphin release in MDD vs. HCs. Further, the Principal
Investigator’s (PI) preliminary studies suggest that smartphone-administered ecological momentary assessment
(EMA) of daily stressors is greater in depressed relative to control participants and has distinct structural and
functional neural correlates. In this study, EMA of daily stressors will be acquired and evaluated to determine if
daily stress preceding the PET scan, as well as preceding a structural magnetic resonance imaging (MRI) scan,
modulate brain structure, KOR binding, and stress-induced endogenous dynorphin release in depression. This
will be the first study to investigate KOR’s role in stress-reactivity in vivo in MDD, and will combine multimodal
neuroimaging, peripheral markers of HPA activation, and EMA daily stress. Regardless of the outcome of this
study, it will increase our understanding of KOR’s role in MDD and in dysregulated stress reactivity in MDD,
potentially suggesting KOR-regulated, stress-sensitive depression subtypes. This award will measurably
advance the PI’s training in conducting highly impactful research studies and understanding the neurobiology of
mood disorders. This will propel the PI toward research independence, launching her research program aimed
at elucidating the consequences of stress in mood disorders and developing interventions to mitigate them.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PET imaging of dynorphin/kappa-opioid reactivity to stress in depression
-
批准号:10590882
-
项目类别:
-
资助金额:$18.13万
-
财政年份:2022
-
负责人:Elizabeth Adams Bartlett
-
依托单位:
海外基金